Profile picture of ABC News
$2.9 million gene therapy for severe hemophilia is approved by FDA: U.S. health regulators have approved a gene therapy for the most common form of hemophilia
abcnews.go.com/Business/wireStory/gene-therapy-severe-hemophilia-approved-fda-100508774
$2.9 million gene therapy for severe hemophilia is approved by FDA
Quick Glance: BioMarin receives FDA approval for gene therapy in hemophilia A
  • BioMarin announces FDA approval of gene therapy for severe hemophilia A.

  • Roctavian gene therapy offers an alternative to regular injections of missing blood proteins.

  • Roctavian is priced at $2.9 million.

  • Pivotal trial results show that Roctavian reduces bleeding events, but its long-term durability is unknown.
Profile picture of Bloomberg
BioMarin’s Gene Therapy Cuts Annual Bleeds by 80% Over 3 Years: BioMarin Pharmaceutical Inc.’s gene therapy Roctavian reduced the annualized rate of bleeding in ...
bloomberg.com/news/articles/2023-01-08/biomarin-s-gene-therapy-cuts-annual-bleeds-by-80-over-3-years
BioMarin’s Gene Therapy Cuts Annual Bleeds by 80% Over 3 Years
Profile picture of Deutsches Ärzteblatt
First gene therapy for hemophilia A before approval: Amsterdam - The European Medicines Agency (EMA) has given the go-ahead for the first gene therapy for ...
aerzteblatt.de/nachrichten/135470/Erste-Gentherapie-der-Haemophilie-A-vor-der-Zulassung
First gene therapy for hemophilia A before approval